|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00467311 |
|
Date of registration:
|
27/04/2007 |
|
Primary sponsor: |
|
|
Public title:
|
Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients
|
|
Scientific title:
|
Diagnostic, Transversal, Comparative, Not Randomized Trial for the Evaluation of Cystatin C as an Early Marker of Contrast-Medium Nephropathy in High-and-Intermedium-Risk Patients Undergoing to Cardiac Catheterization |
|
Date of first enrolment:
|
December 2006 |
|
Target sample size:
|
66 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00467311 |
|
Study type:
|
Observational |
|
Study design:
|
Time Perspective: Cross-Sectional
|
|
|
Countries of recruitment
|
|
Mexico
| | | | | | | |
|
Contacts
|
|
Name:
|
Jhonathan L Uribe-González, MD, MSc |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Ignacio Chávez National Institute of Cardiology |
|
|
Name:
|
Jorge G Hernández, MD, FSCAI |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Ignacio Chávez National Institute of Cardiology |
|
|
Name:
|
Marco A Martínez-Rios |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Ignacio Chávez National Institute of Cardiology |
|
|
Name:
|
Marco A Peña-Duque, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Ignacio Chávez National Institute of Cardiology |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age over 20 years old
- Indication for coronariography and/or percutaneous coronary intervention
- Voluntary written consent for the realization of coronariography and/or percutaneous
intervention and for the participation in this clinical trial
- A MEHRAN contrast-induced nephropathy score from six to fifteen.
Exclusion Criteria:
- N-Acetylcystein and Fenoldopam pre-medication
- Low risk patients according MEHRAN classification
- Cardiogenic and septic shock
- Acute renal failure by any other cause
- Patients with chronic kidney failure requiring any kind of dialysis
- Patients unable to complete follow-up
- Exposure to contrast media 48 hours prior to study
- Patients unable to give consent
- Receiving contrast media other than non-ionic
Age minimum:
20 Years
Age maximum:
85 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Acute Renal Failure
|
|
Contrast Induced Nephropathy
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|